Absolute quantification of SFRP4 mRNA by real time PCR in biopsies may have a role for risk stratification and treatment selection for prostate cancer patients, including selection of patients for active surveillance and adjuvant treatment. This evidence concerns the gene SFRP4 and prostate cancer.